ホームMCPワークベンチSkills
ホームワークベンチ通知マイページ
llms.txt · MCPガイドプライバシーポリシー · 利用規約 · サポートv1.8.3
  1. ホーム
  2. /化合物

(S)-2-ヒドラジノ-2-メチル-3-(3,4-ジヒドロキシフェニル)プロパン酸

Carbidopa

HCID 34359
反応を作成
印刷

データを補完しています。しばらくしてからページを更新すると最新の内容を表示できます

基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート
部分構造検索類似構造を探す

基本情報

CAS
28860-95-9
標準SMILES
C[C@@](Cc1ccc(O)c(O)c1)(NN)C(=O)O
InChIKey
TZFNLOMSOLWIDK-JTQLQIEISA-N
分子式
C10H14N2O4
平均分子量
226.23 g/mol
単同位体質量
226.09535693

概要

Carbidopa (anhydrous) is 3-(3,4-Dihydroxyphenyl)propanoic acid in which the hydrogens alpha- to the carboxyl group are substituted by hydrazinyl and methyl groups (S-configuration). Carbidopa is a dopa decarboxylase inhibitor, so prevents conversion of levodopa to dopamine. It has no antiparkinson activity by itself, but is used (commonly as its hydrate) in the management of Parkinson's disease to reduce peripheral adverse effects of levodopa. It has a role as an antiparkinson drug, a dopaminergic agent and an EC 4.1.1.28 (aromatic-L-amino-acid decarboxylase) inhibitor. It is a member of hydrazines, a monocarboxylic acid and a member of catechols.

名称と識別子

優先名称
Carbidopa
IUPAC
(2S)-3-(3,4-dihydroxyphenyl)-2-hydrazinyl-2-methylpropanoic acid
現地名
(S)-2-ヒドラジノ-2-メチル-3-(3,4-ジヒドロキシフェニル)プロパン酸
英語名
S-(-)-Carbidopa
分子式
C10H14N2O4
分子量
226.23

名称と別名

carbidopa28860-95-9LodosynCarbidopa anhydrousN-Aminomethyldopa(S)-(-)-carbidopaalpha-MethyldopahydrazineCarbidopumL-alpha-Methyldopahydrazine(2S)-3-(3,4-dihydroxyphenyl)-2-hydrazinyl-2-methylpropanoic acidCarbidopa (anhydrous)(S)-carbidopa
名称をさらに表示
α-メチルドーパヒドラジン(S)-α-ヒドラジノ-3,4-ジヒドロキシ-α-メチルベンゼンプロパン酸カルビドーパ(S)-2-ヒドラジノ-2-メチル-3-(3,4-ジヒドロキシフェニル)プロパン酸ヒドラジノ-α-メチルドーパ(αS)-3,4-ジヒドロキシ-α-ヒドラジノ-α-メチルヒドロけい皮酸N-アミノメチルドーパS-(−)-カルビドパ(2S)-2-ヒドラジノ-2-メチル-3-(3,4-ジヒドロキシフェニル)プロピオン酸(2S)-3-(3,4-ジヒドロキシフェニル)-2-ヒドラジニル-2-メチルプロパン酸L-カルビドーパ(αS)-α-ヒドラジノ-3,4-ジヒドロキシ-α-メチルベンゼンプロパン酸S(-)-CARBIDOPACarbidopa-d3mk486KINSONL-3-(3,4CARBIDOPA EDMFCarbidopa MonomerCARBIDOPAANHYDROUS
MK 486L-3-(3,4-Dihydroxyphenyl)-2-methyl-2-hydrazinopropionic acidMK-486DTXSID4022735(-)-L-alpha-Hydrazino-3,4-dihydroxy-alpha-methylhydrocinnamic acidKR87B45RGH(alphaS)-alpha-hydrazino-3,4-dihydroxy-alpha-methylbenzenepropanoic acidDTXCID502735

データベース識別子

CAS
28860-95-9、38821-49-7
PubChem CID
34359
DTXSID
DTXSID4022735
ChEMBL
CHEMBL1200748、CHEMBL1201236
ChEBI
CHEBI:39585
UNII
KR87B45RGH
EC Number
249-271-9、657-445-4
Nikkaji
J17.160C

物性

構造計算による物性補完中

XLogP
-2.2
極性表面積
116 Ų
水素結合供与体数
5
水素結合受容体数
6
回転可能結合数
4
重原子数
16
形式電荷
0
複雑度
261

実験および物理化学的性質

Drugs · 2 件

Pharmaceuticals -> Listed in ZINC15

Pharmaceuticals -> Used in Switzerland

LogP-1.9
Human Drugs · 3 件

FDA approved drugs -> Active ingredient

FDA approved drugs -> Active ingredient

Pharmaceuticals

Boiling PointDecomposes
Melting Point · 2 件

203-208 °C

203 - 205 °C

Physical DescriptionSolid
Dissociation Constants2.3
Collision Cross Section · 2 件

142.4 Ų [M+H]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]

143.39 Ų [M+H]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]

物理化学的性質

融点
203 · 203-205° (dec); mp 208°
比旋光度
-17.3 ° · D -17.3° (methanol)
沸点
367.84 °C · 367.84°C (rough estimate)
比重(密度)
1.2616 · 1.2616 (rough estimate)
屈折率
1.5 · 1.5000 (estimate)
貯蔵温度
-20 °C · -20°C
溶解性
DMSO(微量)、メタノール(微量)
酸解離定数(Pka)
3.4 · 3.40±0.14(Predicted)
外見
粉
色
ホワイトからオフホワイト
安定性
溶液中で不安定
InChI
InChI=1/C10H14N2O4/c1-10(12-11,9(15)16)5-6-2-3-7(13)8(14)4-6/h2-4,12-14H,5,11H2,1H3,(H,15,16)/t10-/s3
InChIKey
TZFNLOMSOLWIDK-JQHDBZEONA-N
SMILES
[C@@](C)(NN)(C(=O)O)CC1C=CC(O)=C(O)C=1 |&1:0,r|
CAS データベース
28860 · 28860-95-9(CAS DataBase Reference)

化学的性質

化学的特性White Solid

安全と法規制

安全情報は参考情報です。供給元の安全データシート(SDS)、適用法令、専門家による評価に代わるものではありません。

GHS分類

GHS Classification · 6 件

This chemical does not meet GHS hazard criteria for 2.7% (2 of 75) of reports.

Danger

H315 (82.7%): Causes skin irritation [Warning Skin corrosion/irritation]

P203, P261, P264, P264+P265, P271, P280, P302+P352, P304+P340, P305+P351+P338, P318, P319, P321, P332+P317, P337+P317, P362+P364, P403+P233, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 75 reports by companies from 10 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

Warning

危険有害性情報

Regulatory InformationREACH registered substance: Carbidopa (EC: 249-271-9)
Hazard Classes and Categories · 2 件

Skin Irrit. 2 (82.7%)

Muta. 2 (100%)

毒性情報

Adverse Effects · 1 件

Because of the irreversible binding of AADC, carbidopa can decrease or deplete peripheral levels of serotonin, dopamine, norepinephrine, and epinephrine. Additionally, research has demonstrated that the irreversible binding of PLP causes nutritional deficiencies in vitamins B3 and B6. Specific carbidopa-induced dyskinesias, including “facial twitching and head bobbing,” have also been described.

Toxicity Summary · 1 件

There is little data to suggest a possibility for or symptoms of carbidopa toxicity. However, reported data indicate that carbidopa/levodopa intestinal gel infusion can cause significant damage to small nerve fibers leading to pain and sensory discomfort.

Drug Induced Liver Injury · 6 件

Drug Induced Liver Injury Rank (DILIrank 2.0)

Carbidopa

Ambiguous-DILI-concern

3

Warnings & precautions

DOI:10.1016/j.drudis.2016.02.015

EPA Human Health Benchmarks for Pharmaceuticals · 6 件

Carbidopa

1.6

6.9

Most patients respond to a 1:10 proportion of carbidopa and levodopa, provided the daily dosage of carbidopa is 70 mg or more a day.

Data used to generate the benchmarks include the following: Lowest Daily Dose (LDD): 70 mg/day, Lowest Therapeutic Dose (LTD): 0.9 mg/kg-day, and Screening Dose: 0.0003 mg/kg-day.

2-Jul-20

安全データ

wgk
3
rtecs
MW5298000
ストレージクラス
11 - Combustible Solids

化学と産業

薬理情報

Protein BindingIt is widely accepted that the protein binding of carbidopa is 76%. However, more studies are required or the presentation of the source of this information.
Pharmacodynamics · 1 件

When mixed with [levodopa], carbidopa inhibits the peripheral conversion of [levodopa] to dopamine and the decarboxylation of [oxitriptan] to serotonin by aromatic L-amino acid decarboxylase. This results in an increased amount of [levodopa] and [oxitriptan] available for transport to the central nervous system. Carbidopa also inhibits the metabolism of [levodopa] in the GI tract, thus, increasing the bioavailability of [levodopa]. The presence of additional units of circulating [levodopa] can increase the effectiveness of the still functional dopaminergic neurons and it has been shown to alleviate symptoms for a time. The action of carbidopa is very important as [levodopa] is able to cross the blood-brain barrier while dopamine cannot. Hence the administration of carbidopa is essential to prevent the transformation of external [levodopa] to dopamine before reaching the main action site in the brain. The coadministration of carbidopa with [levodopa] has been shown to increase the half-life of [levodopa] more than 1.5 times while increasing the plasma level and decreasing clearance. The combination therapy has also shown an increase of the recovery of [levodopa] in urine instead of dopamine which proves a reduced metabolism. This effect has been highly observed by a significant reduction in [levodopa] requirements and a significant reduction in the presence of side effects such as nausea. It has been observed that the effect of carbidopa is not dose-dependent.

Mechanism of Action · 1 件

Carbidopa is an inhibitor of the DDC which in order, inhibits the peripheral metabolism of levodopa. DDC is very important in the biosynthesis of L-tryptophan to serotonin and the modification of L-DOPA to dopamine. DDC can be found in the body periphery and in the blood-brain barrier. The action of carbidopa is focused on peripheral DDC as this drug cannot cross the blood-brain barrier. Hence, it will prevent the metabolism of [levodopa] in the periphery but it will not have any activity on the generation of dopamine in the brain.

Biological Half-LifeThe reported half-life of carbidopa is of approximately 107 minutes.
Metabolism/Metabolites · 1 件

The loss of the hydrazine functional group (probably as molecular nitrogen) represents the major metabolic pathway for carbidopa. There are several metabolites of carbidopa metabolism including 3-(3,4-dihydroxyphenyl)-2-methylpropionic acid, 3-(4-hydroxy-3-methoxyphenyl)-2-methylpropionic acid, 3-(3-hydroxyphenyl)-2-methylpropionic acid, 3-(4-hydroxy-3-methoxyphenyl)-2-methyllactic acid, 3-(3-hydroxyphenyl)-2-methyllactic acid, and 3,4-dihydroxyphenylacetone (1,2).

FDA Pharmacological Classification · 5 件

MNX7R8C5VO

CARBIDOPA

Established Pharmacologic Class [EPC] - Aromatic Amino Acid Decarboxylation Inhibitor

Mechanisms of Action [MoA] - DOPA Decarboxylase Inhibitors

Carbidopa is an Aromatic Amino Acid Decarboxylation Inhibitor. The mechanism of action of carbidopa is as a DOPA Decarboxylase Inhibitor.

MeSH Pharmacological Classification · 3 件

Agents used in the treatment of Parkinson's disease. The most commonly used drugs act on the dopaminergic system in the striatum and basal ganglia or are centrally acting muscarinic antagonists.

Any drugs that are used for their effects on dopamine receptors, on the life cycle of dopamine, or on the survival of dopaminergic neurons.

Compounds and drugs that block or inhibit the enzymatic action of AROMATIC AMINO ACID DECARBOXYLASES. Pharmaceutical agents in this category are used in conjunction with LEVODOPA in order to slow its metabolism.

Absorption, Distribution and Excretion · 4 件

When [levodopa]/carbidopa is administered orally, 40-70% of the administered dose is absorbed. Once absorbed, carbidopa shows bioavailability of 58%. A maximum concentration of 0.085 mcg/ml was achieved after 143 min with an AUC of 19.28 mcg.min/ml.

In animal studies, 66% of the administered dose of carbidopa was eliminated via the urine while 11% was found in feces. These studies were performed in humans and it was observed a urine excretion covering 50% of the administered dose.

The volume of distribution reported for the combination therapy of carbidopa/[levodopa] is of 3.6 L/kg. However, carbidopa is widely distributed in the tissues, except in the brain. After one hour, carbidopa is found mainly in the kidney, lungs, small intestine and liver.

The reported clearance rate for the combination therapy of [levodopa]/carbidopa is 51.7 L/h.

用途と製造

UsesUse (kg; approx.) in Germany (2009): >5000
Use ClassificationPharmaceuticals

応用分野

使用in combinaison with levodopa as antiparkinsonian;inhibits aromatic-L-amino-acid decarboxylase (DOPA Decarboxylase or DDC)

一般的な説明Carbidopa is used for treating restless legs (RL) syndrome and periodic leg movements in sleep (PLMS). Carbidopa along with levodopa is used to treat Parkinson′s disease.

上流・下流製品情報

上流原料

4-エテニルフェノールSodium bisulfite water solutionジエチルアミン亜硫酸水素ナトリウム4-ヒドロキシフェニルアセトンn-ブチルアミンシアン化ナトリウムバニリンニトロエタンシアン化カリウム塩酸鉄粉ヒドラジン一水和物臭化水素酸酢酸
補足説明 · 1 件

定義ChEBI: 3-(3,4-Dihydroxyphenyl)propanoic acid in which the hydrogens alpha- to the carboxyl group are substituted by hydrazinyl and methyl groups (S-configuration). Carbidopa is a dopa decarboxylase inhibitor, so prevents conversi n of levodopa to dopamine. It has no antiparkinson activity by itself, but is used (commonly as its hydrate) in the management of Parkinson's disease to reduce peripheral adverse effects of levodopa.

関連反応

6 件
反応記録を作成
HRID 452338 の反応式
HRID 452338生成物として
HRID 452339 の反応式
HRID 452339反応物として
HRID 2212438 の反応式
HRID 2212438反応物として
HRID 2212446 の反応式
HRID 2212446反応物として
HRID 2212452 の反応式
HRID 2212452反応物として
HRID 2242762 の反応式
HRID 2242762反応物として

化合物ノート

このページの内容基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート